Ginkgo Bioworks Holdings, Inc. DNA
We take great care to ensure that the data presented and summarized in this overview for Ginkgo Bioworks Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DNA
View all-
Viking Global Investors LP143MShares$893 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA139MShares$867 Million0.0% of portfolio
-
Baillie Gifford & CO134MShares$839 Million0.04% of portfolio
-
Anchorage Capital Group, L.L.C. New York, NY69.9MShares$436 Million7.28% of portfolio
-
Black Rock Inc. New York, NY42MShares$262 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny31.4MShares$196 Million0.02% of portfolio
-
Legal & General Group PLC London, X027MShares$169 Million0.0% of portfolio
-
Glenview Capital Management, LLC New York, NY26.5MShares$165 Million0.17% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X024.4MShares$152 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl23.9MShares$149 Million0.07% of portfolio
Latest Institutional Activity in DNA
Top Purchases
Top Sells
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Insider Transactions at DNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 02
2024
|
Steven P. Coen Officer |
SELL
Open market or private sale
|
Direct |
17,486
-7.78%
|
$0
$0.29 P/Share
|
|
Aug 02
2024
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
63,567
-5.52%
|
$0
$0.29 P/Share
|
|
Aug 01
2024
|
Steven P. Coen Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,746
+6.21%
|
-
|
|
Aug 01
2024
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
108,127
+2.31%
|
-
|
|
Jul 02
2024
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
49,162
-4.5%
|
$0
$0.33 P/Share
|
|
Jul 02
2024
|
Steven P. Coen Officer |
SELL
Open market or private sale
|
Direct |
13,520
-6.48%
|
$0
$0.33 P/Share
|
|
Jul 01
2024
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
108,126
+2.44%
|
-
|
|
Jul 01
2024
|
Steven P. Coen Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,746
+6.66%
|
-
|
|
Jun 12
2024
|
Harry Sloan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,263
+11.33%
|
-
|
|
Jun 12
2024
|
Christian O Henry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,263
+7.29%
|
-
|
|
Jun 12
2024
|
Shyam Sankar Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,263
+4.1%
|
-
|
|
Jun 12
2024
|
Arie Belldegrun Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,263
+35.07%
|
-
|
|
Jun 12
2024
|
Kathy Hopinkah Hannan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,263
+38.63%
|
-
|
|
Jun 12
2024
|
Marijn E Dekkers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,263
+21.41%
|
-
|
|
Jun 12
2024
|
Reshma Kewalramani Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,263
+36.14%
|
-
|
|
Jun 03
2024
|
Steven P. Coen Officer |
SELL
Open market or private sale
|
Direct |
13,440
-6.99%
|
$0
$0.55 P/Share
|
|
Jun 03
2024
|
Mark E. Dmytruk Officer |
SELL
Open market or private sale
|
Direct |
48,866
-4.73%
|
$0
$0.55 P/Share
|
|
May 31
2024
|
Steven P. Coen Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,745
+7.18%
|
-
|
|
May 31
2024
|
Mark E. Dmytruk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
108,128
+2.57%
|
-
|
|
May 16
2024
|
Marijn E Dekkers Director |
SELL
Open market or private sale
|
Indirect |
265,000
-4.58%
|
$0
$0.83 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 2.26M shares |
|---|---|
| Open market or private purchase | 923K shares |
| Conversion of derivative security | 400K shares |
| Open market or private sale | 9.59M shares |
|---|---|
| Bona fide gift | 400K shares |